MSc, Biochemistry, University of Ottawa, Ottawa, Ontario, Canada
BSc, Biochemistry, Queen’s University, Kingston, Ontario, Canada

Andrea brings with her over 5 years of experience in clinical research and basic research. Prior to joining PDCI in September 2016, Andrea worked as a Clinical Researcher at Canada’s Drug Agency (CDA-AMC, formerly CADTH), where she reviewed drug submissions for the purpose of informing reimbursement decisions by Canada’s public drug plans.

At PDCI, Andrea’s leads the HTA and Clinical Evaluation team, critically appraising clinical evidence and synthesizing information to develop optimal positioning of a product for market access strategies and health technology assessment/payer submissions. Andrea has worked in numerous therapeutic areas throughout her time at CDA-AMC and PDCI, which allows her to provide valuable insights in a wide range of drug products. She has extensive experience in the rare disease space.

Andrea’s passion for her work, combined with her exceptional skills and experience, make her an outstanding partner for our clients. Her dedication to delivering high-quality outcomes is evident in every aspect of her work.